Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
26 hedge funds and large institutions have $11.8M invested in Aevi Genomic Medicine Inc in 2013 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
13% more funds holding
Funds holding: 23 → 26 (+3)
1% more capital invested
Capital invested by funds: $11.8M → $11.8M (+$62.4K)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$703K |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$509K |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$367K |
| 4 |
WA
WFG Advisors
Dallas,
Texas
|
+$65.4K |
| 5 |
VanEck Associates
New York
|
+$57.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$580K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$192K |
| 3 |
Morgan Stanley
New York
|
-$165K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$129K |
| 5 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
-$117K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
HighTower Advisors
Chicago,
Illinois
| – | -$129K | -16,600 | Closed |
|
|
CA
27
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
| – | -$117K | -15,000 | Closed |
|
28
Bank of America
Charlotte,
North Carolina
| – | +$334 | +51 | New |
|
GNMX Hedge Fund Activity: Q4 2013 in Review
26 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q4 2013, worth a combined $11.8M — up 0.53% from $11.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new GNMX positions and 3 closed out — a net gain of 3 holders — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $703K. The largest seller was Perceptive Advisors, cutting an estimated $580K.
- 26 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q4 2013, up from 23 in Q3 2013.
- Funds reported $11.8M of Aevi Genomic Medicine Inc stock for Q4 2013, up 0.53% quarter-over-quarter.
- 6 funds opened new Aevi Genomic Medicine Inc positions in Q4 2013 and 3 closed out, a net change of +3 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q4 2013 was Vanguard Group, an estimated $703K added.
- The largest Aevi Genomic Medicine Inc seller in Q4 2013 was Perceptive Advisors, an estimated $580K sold.
Based on aggregated 13F filings for Q4 2013.